Clene Inc CLNN 深 滬
等待開盤 01-28 09:30:00 美东时间
5.19
+0.120
+2.37%
華盛通- 最 高5.25
- 今 開5.09
- 成交量 6.69万股
- 最 低 4.93
- 昨 收 5.07
- 總市值 5363.35万
- 52周最高 13.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.2801
- 委 比 25.65%
- 總股本 1033.40万
- 歷史最高 356.40
- 量 比 0.59
- 振 幅 6.31%
- 歷史最低 2.2801
- 每 手 1
- 風險率 2.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
Insiders have been trading these 5 stocks: (($MDGL)), (($CLNN)), (($COR)), (($S...
01-24 21:00
10% Owner Chidozie Ugwumba Reports Disposal of Clene Inc. Common Shares
10% Owner Chidozie Ugwumba Reports Disposal of Clene Inc. Common Shares Chidozie Ugwumba, a 10% owner of Clene Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT
01-22 07:14
Clene to Present at the Emerging Growth Conference
Clene Inc. (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. announced that management will present at the Emerging Growth Conference on January 21, 2026, at 3:10 p.m. ET. The presentation will be available via webcast, with a replay accessible through the conference portal and YouTube. Clene focuses on improving mitochondrial health to treat neurodegenerative diseases like ALS and MS, and its investigational therapy CNM-Au8® targets mito...
01-16 13:30
Clene Announces Multi-Tranche Financing to Extend Cash Runway
Clene ( ($CLNN) ) just unveiled an update. On January 8, 2026, Clene Inc. enter...
01-14 05:54
Clene Advances CNM-Au8 ALS Program with FDA Meeting
Clene ( ($CLNN) ) has shared an announcement. On January 12, 2026, Clene Inc. a...
01-12 22:12
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
Clene Inc. announced the FDA has granted an in-person Type C meeting in Q1 2026. New analyses show modest NfL reductions (~10%) are significantly associated with lower mortality risk in ALS, supporting NfL as a surrogate endpoint for accelerated approval. Exploratory data from the HEALEY trial shows CNM-Au8 30mg treatment in responders with IGFBP7 biomarker decline was associated with 78% reduced mortality risk (HR 0.22, p=0.01). These findings a...
01-12 13:30
Clene announces registered direct offering of over $28M
Clene (CLNN) on Friday announced a registered direct offering priced above market under Nasdaq rules of over $28 million by new and existing investors. On January 9, 2026, Clene entered into securitie...
01-09 22:40
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
01-09 21:57
Clene Commences $28M Offering Of Securities
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the
01-09 21:41
